BRIEF-Achillion announces initiation of patient dosing in phase 2 study of ACH-4471
April 06, 2017 at 06:25 AM EDT
* Achillion announces initiation of patient dosing in phase 2 study of ACH-4471 for paroxysmal nocturnal hemoglobinuria
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|